Cargando…

Optimal Ratio of Transcription Factors for Somatic Cell Reprogramming

Somatic cell reprogramming is achieved by four reprogramming transcription factors (RTFs), Oct3/4, Sox2, Klf4, and c-Myc. However, in addition to the induction of pluripotent cells, these RTFs also generate pseudo-pluripotent cells, which do not show Nanog promoter activity. Therefore, it should be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagamatsu, Go, Saito, Shigeru, Kosaka, Takeo, Takubo, Keiyo, Kinoshita, Taisuke, Oya, Mototsugu, Horimoto, Katsuhisa, Suda, Toshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2012
Materias:	Cell Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476294/ https://www.ncbi.nlm.nih.gov/pubmed/22955270 http://dx.doi.org/10.1074/jbc.M112.380683

Ejemplares similares

A Germ Cell-specific Gene, Prmt5, Works in Somatic Cell Reprogramming
por: Nagamatsu, Go, et al.
Publicado: (2011)

Integrative Analysis of the Acquisition of Pluripotency in PGCs Reveals the Mutually Exclusive Roles of Blimp-1 and AKT Signaling
por: Nagamatsu, Go, et al.
Publicado: (2015)

Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report
por: Hongo, Hiroshi, et al.
Publicado: (2020)

A Case of Bladder-Inverted Papilloma after Brachytherapy for Prostate Cancer
por: Ezaki, Taisuke, et al.
Publicado: (2014)

Proliferation Rate of Somatic Cells Affects Reprogramming Efficiency
por: Xu, Yongyu, et al.
Publicado: (2013)

Role of the MUC1‐C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2020)

Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?
por: Kosaka, Takeo, et al.
Publicado: (2014)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer
por: Hongo, Hiroshi, et al.
Publicado: (2018)

Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report
por: Kosaka, Takeo, et al.
Publicado: (2019)

A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation
por: Kosaka, Takeo, et al.
Publicado: (2019)

Use of Imaging Techniques to Illuminate Dynamics of Hematopoietic Stem Cells and Their Niches
por: Morikawa, Takayuki, et al.
Publicado: (2017)

Cell division- and DNA replication-free reprogramming of somatic nuclei for embryonic transcription
por: Tomikawa, Junko, et al.
Publicado: (2021)

A Case of Bladder Cancer after Radiation Therapy for Prostate Cancer
por: Kaburaki, Naoto, et al.
Publicado: (2014)

Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel
por: Kosaka, Takeo, et al.
Publicado: (2018)

Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
por: Watanabe, Keitaro, et al.
Publicado: (2021)

Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Correction: CLEC-2 in megakaryocytes is critical for maintenance of hematopoietic stem cells in the bone marrow
por: Nakamura-Ishizu, Ayako, et al.
Publicado: (2015)

CLEC-2 in megakaryocytes is critical for maintenance of hematopoietic stem cells in the bone marrow
por: Nakamura-Ishizu, Ayako, et al.
Publicado: (2015)

Network evaluation from the consistency of the graph structure with the measured data
por: Saito, Shigeru, et al.
Publicado: (2008)

In vivo Reprogramming of Adult Somatic Cells to Pluripotency by Overexpression of Yamanaka Factors
por: Yilmazer, Açelya, et al.
Publicado: (2013)

Splenic cord capillary hemangioma with non-islet cell tumor hypoglycemia: a case report
por: Daimon, Tatsuaki, et al.
Publicado: (2019)

Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer
por: Takayama, Ken-ichi, et al.
Publicado: (2021)

Brachytherapy seeds as a nidus for urethral stone formation: A case report
por: Kamisawa, Ken, et al.
Publicado: (2019)

Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Yasumizu, Yota, et al.
Publicado: (2021)

IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer
por: Shigeta, Keisuke, et al.
Publicado: (2023)

The dynamics of chromatin states mediated by epigenetic modifications during somatic cell reprogramming
por: Peng, Jing, et al.
Publicado: (2023)

Epithelial-Mesenchymal Transition and Metabolic Switching in Cancer: Lessons From Somatic Cell Reprogramming
por: Lai, Xiaowei, et al.
Publicado: (2020)

Chromatin accessibility in canine stromal cells and its implications for canine somatic cell reprogramming
por: Questa, Maria, et al.
Publicado: (2020)

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
por: Komori, Takahiro, et al.
Publicado: (2022)

Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity
por: Kosaka, Takeo, et al.
Publicado: (2013)

Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2017)

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2018)

Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Squamous cell carcinoma of the prostate with SMARCA4 alteration in a Japanese patient
por: Kaneko, Yuta, et al.
Publicado: (2022)

The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation
por: Hongo, Hiroshi, et al.
Publicado: (2022)

Genomic analysis of aggressive ductal adenocarcinoma of the prostate
por: Kobayashi, Hiroaki, et al.
Publicado: (2022)

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis
por: Kubota, Yoshiaki, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_poihluim84l5lio58he91k0su6